On June 12, Duality Biotherapeutics-B (mapped as DualityBio) rose 5.25% in regular trading, reaching HK$188.2 per share with turnover of HK$146 million, rebounding sharply from consecutive declines of 5.25% and 5.61% on June 8 and June 11 respectively.

On the news front, the company announced on June 10 that its STAR Market (Science and Technology Innovation Board) IPO guidance conducted by CITIC Securities has passed the verification by the Shanghai Bureau of the China Securities Regulatory Commission, marking a key milestone in its dual-listing strategy. This progress signals expanded capital market access and additional funding channels for its ADC pipeline development. Meanwhile, the company has maintained its buyback program, repurchasing 10,000 shares on June 10 at approximately HK$167.42 per share.

Within the Biotechnology sector, the overall tone turned positive. Among individual stocks, Remegen up 7.68%, Akeso up 5.58%, Innovent Bio up 4.46%, 3SBio up 2.89%, BeiGene up 1.42%, indicating a broad sector recovery from the prior session's collective selloff.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)